Drug Profile

TN 401

Alternative Names: TN-401

Latest Information Update: 26 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tenaya Therapeutics
Class Cardiovascular therapies; Gene therapies
Mechanism of Action Gene transference; Plakophilin 2 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Arrhythmogenic right ventricular dysplasia
New Molecular Entity No

Highest Development Phases

Phase I/II Arrhythmogenic right ventricular dysplasia

Most Recent Events

15 May 2026 TN 401 receives Priority Medicine (PRIME) status for Arrhythmogenic right ventricular dysplasia in European Union
15 May 2026 Efficacy, adverse events and pharmacodynamics data from the phase Ib/II RIDGE-1 trial in Arrhythmogenic right ventricular dysplasia released by Tenaya Therapeutics
12 Mar 2026 Tenaya Therapeutics has protection for TN 401

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com